A QSAR study on some series of anti-hepatitis C virus (HCV) agents

Letters in Drug Design and Discovery

Volumn 7, Issue 2, 2010, Pages 139-148

  Patil, Vaishali M ^a   Gupta, S P ^a   Samanta, S ^b  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Anti hepatitis C virus (HCV) agents; Benzimidazole coumarin conjugates; Hepatitis C virus inhibitors; Pyrrolo 2,3 d pyrimidine nucleoside derivatives; QSAR study; Ribonucleoside analogues

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE COUMARIN CONJUGATE; COUMARIN DERIVATIVE; PYRROLO[2,3 D]PYRIMIDINE NUCLEOSIDE DERIVATIVE; RIBONUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SCREENING; HEPATITIS C; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 77949702731     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010790225877     Document Type: Article

References (20)

1. Penin, F.; Dubuisson, J.; Rey, F. A.; Moradpour, D.; Pawlotsky, J.-M.; Structural biology of hepatitis C virus. Hepatology, 2004, 39, 5-19.
2. Armstrong, G. L.; Alter, M. J.; McQuillan, G. M.; Margolis, H. S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the united states. Hepatology, 2000, 31, 777-782.
3. Condron, S.L.; Heneghan, M.A.; Patel, K.; Dev, A.; McHutchison, J.G.; Muir, A.J. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation, 2005, 80, 145-148.
4. Bretner, M. Existing and future therapeutic options for hepatitis C virus infection. Acta Biochim. Pol., 2005, 52, 57-70.
5. Pawlotsky, J. M.; Gish, R. G. Future therapies for hepatitis C. Antivir. Ther., 2006, 11, 397-408.
6. Neyts, J. Selective inhibitors of hepatitis C virus replication. Antivir. Res., 2006, 71, 363-371.
7. Chun, B. K.; Wang, P.; Hasan, A.; Du, J.; Tharnish, P. M.; Stuyver, L. J.; Otto, M. J.; Schinazi, R. F.; Watanabe, K. A. Synthesis of 5′,9-anhydro-3-(β-d-ribofuranosyl)xanthine, and 3,5′-anhydro- xanthosine as potential antihepatitis C virus agents. Tetrahedron Lett., 2005, 46, 2825-27.
8. Gopalsamy, A.; Chopra, R.; Lim, K.; Ciszewski, G.; Shi, M.; Curran, K. J.; Sukits, S. F.; Svenson, K.; Bard, J.; Ellingboe, J.W.; Agarwal, A.; Krishnamurthy, G.; Howe, A.Y. M.; Orlowski, M.; Feld, B.; O'Connell, J.; Mansour, T. S. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5B polymerase inhibitor. Evidence for a new NS5B polymerase binding site. J. Med. Chem., 2006, 49, 3052-3055.
9. Middleton, T.; Lim, H. B.; Montgomery, D; Rockway, T.; Liu, D.; Klein, L.; Qin, W.; Harlan, J.E.; Kati, W.M.; Molla, A. Azapteridine inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Lett. Drug Des. Discov., 2007, 4, 1-8.
10. Harper, S.; Pacini, B.; Avolio, S.; Filoppo, M. D.; Mgliaccio, G.; Laufer, R.; Francesco, R.D.; Rowley, M.; Narjes, F. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J. Med. Chem., 2005, 48, 1314-1317.
11. Fitch, D. M.; Evans, K. A.; Chai, D.; Duffy, K. J. A highly efficient, asymmetric synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Org. Lett., 2005, 7, 5521-5524.
12. Priestley, E. S.; Decicco, C.P. 1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatits C virus NS3 protease. Org. Lett., 2000, 2, 3095-3097.
13. Venkatraman, S.; Njoroge, G.; Girijavallabhan, V.M.; Madison, V. S.; Yao, N. H.; Prongay, A. J.; Butkiewicz, N.; Pichardo, J. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design. J. Med. Chem., 2005, 48, 5088-5091.
14. Ichikawa, E.; Kato, K.; Sugar-modified nucleoside in past 10 years, a review. Curr. Med. Chem., 2001, 8, 385-423.
15. Varaprasad, C. V. N. S.; Ramasamy, K. S.; Girardet, J. L.; Gunic, E.; Lai, V.; Zhong, W.; An, H.; Hong, Z. Synthesis of pyrrolo[2,3-d]pyrimidine nucleoside derivatives as potential anti- HCV agents. Bioorg. Chem., 2007, 35, 25-34.
16. Hwu, J. R.; Singha, R.; Hong, S. H.; Chang, Y. H.; Das, A. R.; Vliegen, I.; Clercq, E. D.; Neyts, J. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antivir. Res., 2008, 77, 157-162.
17. Gunic, E.; Chow, S.; Rong, F.; Ramasamy, K.; Raney, A.; Li, D. Y.; Huang, J.; Hamatake, R. K.; Hong, Z.; Girardet, J.-L. 6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophosphate prodrugs as potent hepatitis C virus inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2456-2458.
18. Ikejiri, M.; Ohshima, T.; Kato, K.; Toyama, M.; Murata, T.; Shimotohno, K.; Maruyama, T. 5-O-Masked 2-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents. Bioorg. Med. Chem., 2007, 15, 6882-6892.
19. Kier, L. B.; Hall, L. H. Molecular Connectivity in Drug Research. Academic Press: New York, 1976.
20. Kier, L. B.; Hall, L. H. General definition of valence delta-values for molecular connectivity. J. Pharm. Sci., 1983, 72, 1170-1173.